Mayinglong Pharmaceutical Group Co Ltd (600993) - Net Assets

Latest as of September 2025: CN¥4.43 Billion CNY ≈ $648.47 Million USD

Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has net assets worth CN¥4.43 Billion CNY (≈ $648.47 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.34 Billion ≈ $781.60 Million USD) and total liabilities (CN¥909.82 Million ≈ $133.14 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 600993 asset liquidity ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	CN¥4.43 Billion
% of Total Assets	82.97%
Annual Growth Rate	14.9%
5-Year Change	42.58%
10-Year Change	122.7%
Growth Volatility	27.25

Mayinglong Pharmaceutical Group Co Ltd - Net Assets Trend (2001–2024)

This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Mayinglong Pharmaceutical Group Co Ltd for the complete picture of this company's asset base.

Annual Net Assets for Mayinglong Pharmaceutical Group Co Ltd (2001–2024)

The table below shows the annual net assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2024. For live valuation and market cap data, see 600993 company net worth.

Year	Net Assets	Change
2024-12-31	CN¥4.20 Billion ≈ $614.78 Million	+8.56%
2023-12-31	CN¥3.87 Billion ≈ $566.29 Million	+6.94%
2022-12-31	CN¥3.62 Billion ≈ $529.55 Million	+9.19%
2021-12-31	CN¥3.31 Billion ≈ $484.97 Million	+12.48%
2020-12-31	CN¥2.95 Billion ≈ $431.18 Million	+11.83%
2019-12-31	CN¥2.63 Billion ≈ $385.58 Million	+12.04%
2018-12-31	CN¥2.35 Billion ≈ $344.15 Million	+3.56%
2017-12-31	CN¥2.27 Billion ≈ $332.31 Million	+12.60%
2016-12-31	CN¥2.02 Billion ≈ $295.13 Million	+6.91%
2015-12-31	CN¥1.89 Billion ≈ $276.06 Million	+11.05%
2014-12-31	CN¥1.70 Billion ≈ $248.58 Million	+8.46%
2013-12-31	CN¥1.57 Billion ≈ $229.19 Million	+9.28%
2012-12-31	CN¥1.43 Billion ≈ $209.74 Million	+8.59%
2011-12-31	CN¥1.32 Billion ≈ $193.15 Million	+17.10%
2010-12-31	CN¥1.13 Billion ≈ $164.95 Million	+7.18%
2009-12-31	CN¥1.05 Billion ≈ $153.90 Million	+20.69%
2008-12-31	CN¥871.43 Million ≈ $127.52 Million	+2.15%
2007-12-31	CN¥853.12 Million ≈ $124.84 Million	-0.24%
2006-12-31	CN¥855.21 Million ≈ $125.14 Million	+43.36%
2005-12-31	CN¥596.55 Million ≈ $87.29 Million	+8.03%
2004-12-31	CN¥552.20 Million ≈ $80.80 Million	+138.69%
2003-12-31	CN¥231.35 Million ≈ $33.85 Million	+13.11%
2002-12-31	CN¥204.54 Million ≈ $29.93 Million	+18.91%
2001-12-31	CN¥172.01 Million ≈ $25.17 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Mayinglong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 6599.6% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component	Amount	Percentage
Retained Earnings	CN¥3.31 Billion	81.48%
Common Stock	CN¥431.05 Million	10.60%
Other Comprehensive Income	CN¥299.76 Million	7.37%
Other Components	CN¥22.02 Million	0.54%
Total Equity	CN¥4.07 Billion	100.00%

Mayinglong Pharmaceutical Group Co Ltd Competitors by Market Cap

The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their market capitalization.

Company	Market Cap
Zhejiang Jiahua Energy Chemical Industry Co Ltd SHG:600273	$1.63 Billion
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	$1.63 Billion
Europris ASA OL:EPR	$1.63 Billion
Bellevue Gold Ltd AU:BGL	$1.63 Billion
Hangjin Technology Co Ltd SHE:000818	$1.63 Billion
FRIEDR.VORW.GRP. ADR/025 F:VH20	$1.63 Billion
Bank of Chongqing Co Ltd F:CQN	$1.62 Billion
Attendo AB (publ) ST:ATT	$1.62 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Mayinglong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2023 to 2024, total equity changed from 3,737,968,219 to 4,065,961,926, a change of 327,993,707 (8.8%).
Net income of 528,093,863 contributed positively to equity growth.
Dividend payments of 177,280,794 reduced retained earnings.
Other comprehensive income increased equity by 297,678.

Equity Change Factors (2023 to 2024)

Factor	Impact	Contribution
Net Income	CN¥528.09 Million	+12.99%
Dividends Paid	CN¥177.28 Million	-4.36%
Other Comprehensive Income	CN¥297.68K	+0.01%
Other Changes	CN¥-23.12 Million	-0.57%
Total Change	CN¥-	8.77%

Book Value vs Market Value Analysis

This analysis compares Mayinglong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 2.72x
The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
The price-to-book ratio has decreased from 76.19x to 2.72x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2001-12-31	CN¥0.34	CN¥25.80	x
2002-12-31	CN¥0.41	CN¥25.80	x
2003-12-31	CN¥0.47	CN¥25.80	x
2004-12-31	CN¥1.21	CN¥25.80	x
2005-12-31	CN¥1.30	CN¥25.80	x
2006-12-31	CN¥1.42	CN¥25.80	x
2007-12-31	CN¥1.67	CN¥25.80	x
2008-12-31	CN¥1.83	CN¥25.80	x
2009-12-31	CN¥2.21	CN¥25.80	x
2010-12-31	CN¥2.38	CN¥25.80	x
2011-12-31	CN¥2.71	CN¥25.80	x
2012-12-31	CN¥2.97	CN¥25.80	x
2013-12-31	CN¥3.30	CN¥25.80	x
2014-12-31	CN¥3.66	CN¥25.80	x
2015-12-31	CN¥4.16	CN¥25.80	x
2016-12-31	CN¥4.50	CN¥25.80	x
2017-12-31	CN¥5.07	CN¥25.80	x
2018-12-31	CN¥5.28	CN¥25.80	x
2019-12-31	CN¥5.97	CN¥25.80	x
2020-12-31	CN¥6.60	CN¥25.80	x
2021-12-31	CN¥7.37	CN¥25.80	x
2022-12-31	CN¥8.11	CN¥25.80	x
2023-12-31	CN¥8.69	CN¥25.80	x
2024-12-31	CN¥9.47	CN¥25.80	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Mayinglong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 12.99%
The company shows good efficiency in utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 14.17%
• Asset Turnover: 0.72x
• Equity Multiplier: 1.27x
Recent ROE (12.99%) is below the historical average (13.74%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2001	18.60%	13.44%	0.64x	2.17x	CN¥12.74 Million
2002	18.48%	13.28%	0.68x	2.04x	CN¥15.11 Million
2003	19.42%	12.22%	0.89x	1.80x	CN¥19.30 Million
2004	9.96%	14.19%	0.54x	1.29x	CN¥-190.62K
2005	10.55%	14.59%	0.53x	1.36x	CN¥3.13 Million
2006	11.89%	13.35%	0.49x	1.83x	CN¥11.40 Million
2007	18.57%	24.32%	0.50x	1.52x	CN¥61.55 Million
2008	10.30%	9.93%	0.70x	1.49x	CN¥2.37 Million
2009	18.93%	17.62%	0.71x	1.51x	CN¥84.94 Million
2010	11.98%	10.40%	0.81x	1.42x	CN¥20.23 Million
2011	11.94%	9.83%	0.85x	1.44x	CN¥22.40 Million
2012	13.47%	11.27%	0.84x	1.43x	CN¥44.74 Million
2013	13.07%	11.63%	0.79x	1.42x	CN¥43.74 Million
2014	12.83%	12.43%	0.74x	1.39x	CN¥44.43 Million
2015	12.51%	12.52%	0.74x	1.35x	CN¥44.85 Million
2016	12.90%	11.90%	0.84x	1.29x	CN¥56.22 Million
2017	14.60%	18.28%	0.64x	1.26x	CN¥100.83 Million
2018	7.76%	8.02%	0.75x	1.29x	CN¥-50.87 Million
2019	14.08%	13.31%	0.82x	1.28x	CN¥104.27 Million
2020	14.71%	15.01%	0.72x	1.36x	CN¥134.12 Million
2021	14.65%	13.72%	0.82x	1.30x	CN¥147.45 Million
2022	13.69%	13.55%	0.70x	1.45x	CN¥128.95 Million
2023	11.86%	14.13%	0.65x	1.29x	CN¥69.45 Million
2024	12.99%	14.17%	0.72x	1.27x	CN¥121.50 Million

Industry Comparison

This section compares Mayinglong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

Industry: Drug Manufacturers - Specialty & Generic
Average net assets among peers: $4,691,234,838
Average return on equity (ROE) among peers: 6.16%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Mayinglong Pharmaceutical Group Co Ltd (600993)	CN¥4.43 Billion	18.60%	0.21x	$1.63 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078)	$903.62 Million	4.28%	2.45x	$1.16 Billion
Anhui Fengyuan Pharmaceutical Co Ltd (000153)	$1.22 Billion	5.35%	1.27x	$441.99 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423)	$9.87 Billion	20.71%	0.25x	$5.01 Billion
Livzon Pharmaceutical Group Inc (000513)	$1.07 Billion	3.83%	0.46x	$2.80 Billion
Wedge Industrial Co Ltd (000534)	$1.15 Billion	11.42%	1.59x	$3.04 Billion
Yunnan Baiyao Group Co Ltd (000538)	$9.03 Billion	25.71%	0.43x	$13.75 Billion
Hainan Haiyao Co Ltd (000566)	$275.57 Million	17.28%	1.12x	$947.33 Million
Tus Pharmaceutical Group Co Ltd (000590)	$231.22 Million	-38.13%	1.23x	$389.67 Million
Northeast Pharmaceutical Group Co Ltd (000597)	$4.29 Billion	2.31%	2.07x	$1.03 Billion
Jilin Aodong Pharmaceutical Group Co Ltd (000623)	$18.87 Billion	8.83%	0.08x	$3.32 Billion

About Mayinglong Pharmaceutical Group Co Ltd

SHG:600993 China Drug Manufacturers - Specialty & Generic

Market Cap

$1.63 Billion

CN¥11.12 Billion CNY

Market Cap Rank

#7083 Global

#1668 in China

Share Price

CN¥25.80

Change (1 day)

-0.88%

52-Week Range

CN¥24.76 - CN¥31.00

All Time High

CN¥31.68